Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Protherics was formed in September 1999 from the merger of Proteus International Plc and Therapeutic Antibodies Inc. Protherics is a biopharmaceutical business focused on immunotherapeutic research and development. The company has R&D laboratories in Runcorn, UK, manufacturing facilities in Ceredigion, Wales and Rosedale, Australia, and commercial development, clinical development and regulatory facilities in Nashville, TN. The company's manufacturing facilities meet FDA, MCA, TGA and GMP requirements for the manufacture of biopharmaceuticals.